Buprofess

Buprofess is available as a lemon-flavoured oral powder, packaged in single-dose sachets, which are easy to administer directly onto the tongue without water. 

Two distinct strengths are available, 200 mg or 400 mg, suitable for different age groups and body weights. This differentiation allows for precise and safe dosing, tailored to individual clinical needs.

Buprofess is indicated for the short-term symptomatic treatment of mild to moderate pain, including headache, toothache, muscle pain, minor post-traumatic pain or dysmenorrhoea, as well as for the treatment of fever, regardless of aetiology.

In children and adolescents, the product is used primarily for the control of fever and pain associated with acute infections, in strict compliance with age and weight limits. In adults, Buprofess is an effective option for relieving painful and febrile symptoms, provided it is used for short periods and at the lowest effective doses.

Ibuprofen, the active ingredient, exerts analgesic, antipyretic and anti-inflammatory effects through the reversible inhibition of cyclooxygenases, enzymes involved in the synthesis of prostaglandins, key mediators of inflammation, pain and fever. 

The dosage of Buprofess is determined based on body weight, age and the severity of symptoms. 

For Buprofess 200 mg, children weighing between 20 and 29 kg are given one sachet per dose, up to a maximum of 600 mg per day, whilst for those weighing between 30 and 39 kg, the maximum daily dose is 800 mg. Adolescents and adults may receive 200–400 mg per dose, not exceeding 1200 mg per day.

Buprofess 400 mg is indicated for adolescents and adults weighing over 40 kg, with a usual dose of 400 mg per administration, up to a maximum of 1200 mg per day. The interval between doses must be at least 6 hours.

Buprofess is contraindicated in patients with hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs, as well as in those with a history of severe allergic reactions induced by acetylsalicylic acid. 

Furthermore, it must not be administered in cases of active gastric or duodenal ulcer, gastrointestinal haemorrhage, severe hepatic, renal or cardiac failure, coagulation disorders or active haemorrhage.

Use is contraindicated during the third trimester of pregnancy and in patients with severe dehydration. 

Caution is required in patients with a history of gastrointestinal disease, cardiovascular disorders, hypertension, diabetes mellitus, dyslipidaemia, or in smokers. In elderly patients, the risk of adverse reactions is increased, which is why careful monitoring is recommended.

Prolonged use requires monitoring of renal and hepatic function and blood counts.

The most common adverse reactions are gastrointestinal in nature and include epigastric burning, abdominal pain, nausea, vomiting or diarrhoea. More rarely, gastrointestinal ulcers, haemorrhages, central nervous system disorders such as dizziness or headache, and allergic skin reactions may occur.

Serious adverse reactions, although rare, include renal failure, severe Stevens-Johnson-type skin reactions, cardiovascular events or anaphylactic reactions, which require immediate discontinuation of treatment and medical assessment.

Buprofess may interact with certain medicines, such as oral anticoagulants, glucocorticoids, antiplatelet agents, selective serotonin reuptake inhibitors, diuretics, antihypertensives, lithium, methotrexate and certain quinolone antibiotics.

Please refer to the patient information leaflet for a full list of drug interactions.

An overdose of Buprofess may cause nausea, vomiting, abdominal pain, drowsiness, dizziness, convulsions, low blood pressure or respiratory depression. 

There is no specific antidote and treatment is symptomatic and supportive, which is why it is essential to seek medical advice immediately.

Buprofess must be stored in the original packaging, at temperatures below 25 °C, protected from light and moisture. The medicine must not be used after the expiry date and must be kept out of the sight and reach of children.

• NIH, Ibuprofen
• Medline Plus, Ibuprofen
• PubMed, An overview of the clinical pharmacology of ibuprofen
• Sage Journals, Ibuprofen: a journey from prescription to over-the-counter use